MedTrace Logo

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

NCT00945139 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2015-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin). How Doxil is metabolized and excreted from the body will also be studied.

Conditions

Interventions

DRUG

Doxil

Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1

DRUG

Avastin

First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • NYU Langone Health

    collaborator OTHER

  • New Mexico Cancer Research Alliance

    lead OTHER

Principal Investigators

  • Claire F. Verschraegen, M.D. · University of New Mexico

  • Franco Muggia, MD · New York University Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-12-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945139 on ClinicalTrials.gov